K
Kiyotaka Kawashima
Publications - 7
Citations - 483
Kiyotaka Kawashima is an academic researcher. The author has contributed to research in topics: Cancer & Fibroblast growth factor receptor 3. The author has an hindex of 7, co-authored 7 publications receiving 447 citations.
Papers
More filters
Journal ArticleDOI
Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue.
Erika M. Wolff,Yoshitomo Chihara,Fei Pan,Daniel J. Weisenberger,Kimberly D. Siegmund,Kokichi Sugano,Kiyotaka Kawashima,Peter W. Laird,Peter A. Jones,Gangning Liang +9 more
TL;DR: The hypomethylation present in noninvasive tumors may counterintuitively provide a biological explanation for the failure of these tumors to become invasive and contribute to a loss of epithelial integrity and create a permissible environment for tumors to arise.
Journal ArticleDOI
Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non‐muscle invasive bladder cancer
Makito Miyake,Kokichi Sugano,Hitomi Sugino,Kazuho Imai,Eri Matsumoto,Koshi Maeda,Shinich Fukuzono,Hiroki Ichikawa,Kiyotaka Kawashima,Kaoru Hirabayashi,Tetsuro Kodama,Hiroyuki Fujimoto,Tadao Kakizoe,Yae Kanai,Kiyohide Fujimoto,Yoshihiko Hirao +15 more
TL;DR: Urine FGFR3 mutation assay and cytological examination may be available in the future as complementary diagnostic modalities in postoperative management of NMIBC.
Journal ArticleDOI
1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regulation of p27/Kip1 and G1/G0 Arrest
Makito Miyake,Masazumi Ishii,Naoki Koyama,Kiyotaka Kawashima,Tetsuro Kodama,Satoshi Anai,Kiyohide Fujimoto,Yoshihiko Hirao,Kokichi Sugano +8 more
TL;DR: The effectiveness of molecular targeted approach for bladder UC harboring FGFR3 mutations and the potential utility to decrease the intravesical recurrence of nonmuscle invasive bladder UC after transurethral surgical resection are elucidated.
Journal ArticleDOI
siRNA-mediated knockdown of the heme synthesis and degradation pathways: modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines.
Makito Miyake,Masazumi Ishii,Kiyotaka Kawashima,Tetsuro Kodama,Kokichi Sugano,Kiyohide Fujimoto,Yoshihiko Hirao +6 more
TL;DR: The results suggested that FECH siRNA improved the phototoxicity of ALA‐PDT, overexpression of HO‐1 was associated with shorter (GT)n repeat of the promoter region, and siRNA‐mediated knockdown ofHO‐1 could suppress the growth of bladder cancer cells overexpressing HO‐ 1.
Journal ArticleDOI
Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping.
Makito Miyake,Kokichi Sugano,Kiyotaka Kawashima,Hiroki Ichikawa,Kaoru Hirabayashi,Tetsuro Kodama,Hiroyuki Fujimoto,Tadao Kakizoe,Yae Kanai,Kiyohide Fujimoto,Yoshihiko Hirao +10 more
TL;DR: Somatic mutations of the fibroblast growth factor receptor 3 (FGFR3) gene were detected by peptide nucleic acid (PNA)-mediated real-time PCR clamping and no mutations were detected in tissues and/or urine samples from patients with muscle-invasive bladder cancer or chronic cystitis.